Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

681205

registered interest
date	30/01/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will place in the Library a list of designated centres for the treatment of hidradenitis suppurativa that is difficult to diagnose or manage.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	62194
answer	answer is ministerial correction date of answer 02/02/2017 answer text <p>Hidradenitis suppurativa (HS) can usually be managed through routine access to primary or secondary care. For those patients with the most serious forms of HS, who cannot be managed in this way, a referral to an appropriate specialised service may be appropriate.</p><p> </p><p>The list of specialised dermatology providers for both in-patient and out-patient care is attached.</p><p> </p><p>NHS England commissions specialised services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. The level of service provision nationally is based on an assessment of the likely patient population who will need to access specialised care. It is estimated that about 10% of patients requiring dermatology services (about 10,000 each year) need care from specialised dermatology centres.</p><p> </p><p>More information on the service specification for specialised dermatology can be found at the following link:</p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p> answering member constituency Warrington South answering member printed David Mowat grouped question UIN 62255 question first answered 02/02/2017 16:27:10 answering member 4080 label Biography information for David Mowat attachment 1 file name PQ62194 attached document.XLSX title PQ62194 attached document
tabling member	1538 label Biography information for Rosie Cooper

681213

registered interest
date	30/01/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to NHS England's service specification for specialised dermatology services, if he will place in the Library a list of designated centres for the treatment of hidradenitis suppurativa that is difficult to diagnose or manage.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	62255
answer	answer is ministerial correction date of answer 02/02/2017 answer text <p>Hidradenitis suppurativa (HS) can usually be managed through routine access to primary or secondary care. For those patients with the most serious forms of HS, who cannot be managed in this way, a referral to an appropriate specialised service may be appropriate.</p><p> </p><p>The list of specialised dermatology providers for both in-patient and out-patient care is attached.</p><p> </p><p>NHS England commissions specialised services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. The level of service provision nationally is based on an assessment of the likely patient population who will need to access specialised care. It is estimated that about 10% of patients requiring dermatology services (about 10,000 each year) need care from specialised dermatology centres.</p><p> </p><p>More information on the service specification for specialised dermatology can be found at the following link:</p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p> answering member constituency Warrington South answering member printed David Mowat grouped question UIN 62194 question first answered 02/02/2017 16:27:10 answering member 4080 label Biography information for David Mowat attachment 1 file name PQ62194 attached document.XLSX title PQ62194 attached document
tabling member	1538 label Biography information for Rosie Cooper

535547

registered interest
date	12/07/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment NICE has made of the need for clinical guidelines on hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	42485
answer	answer is ministerial correction date of answer 18/07/2016 answer text <p>The National Institute for Health and Care Excellence (NICE) has advised that it has not made any assessment of the need to develop a clinical guideline on the care of people with hidradenitis suppurativa, nor has it been asked to develop a clinical guideline on this condition.</p><p> </p><p>NICE published technology appraisal guidance on adalimumab (Humira) for treating moderate to severe hidradenitis suppurativa (TA392) on 22 June 2016<em>,</em> which recommends its use. Commissioners now have three months in which to put in place funding arrangements.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 18/07/2016 15:00:05 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	1538 label Biography information for Rosie Cooper

535548

registered interest
date	12/07/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment NHS England has made of the capacity of specialist dermatology centres to support people living with hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	42486
answer	answer is ministerial correction date of answer 18/07/2016 answer text <p>Hidradenitis suppurativa (HS) can usually be managed through routine access to primary or secondary care. For those patients with the most serious forms of HS who cannot be managed in this way, a referral to a specialised service may be appropriate.</p><p> </p><p>NHS England commissions specialised services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. The level of service provision nationally is based on an assessment of the likely patient population who will need to access specialised care. It is estimated that about 10% of patients requiring dermatology services (about 10,000 each year) need care from specialised dermatology centres.</p><p> </p><p>Specialised services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p><br> <a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p> answering member constituency Warrington South answering member printed David Mowat question first answered 18/07/2016 16:23:07 answering member 4080 label Biography information for David Mowat
tabling member	1538 label Biography information for Rosie Cooper

418463

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps NHS England takes to assess the health and social care needs of patients with hidradenitis suppurativa; and what assessment he has made of the ability of the NHS to deliver efficient diagnosis and access to specialist care for such patients.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	10010
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>NHS England works in partnership with local commissioners and providers to ensure people with long-term conditions, such as hidradenitis suppurativa (HS), are supported to live healthily and independently and are empowered to take better control over the care they receive.</p><p> </p><p> </p><p> </p><p>The majority of patients with HS can be managed through routine access to primary and secondary care, including dermatology clinics, which is responsibility of the local National Health Service commissioners. Treatment and management of the condition involves antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe.</p><p> </p><p> </p><p> </p><p>For those patients with the more serious forms of HS, referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions, including HS, and has set out what providers must have in place in order to offer specialist dermatology care. This supports equity of access to a high quality service for patients wherever they live. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found by viewing the specialised dermatology service specification at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 10011 question first answered 16/09/2015 11:46:53 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

418464

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what progress has been made by NHS England on the production of a commissioning policy for treatments associated with hidradenitis suppurativa; what the proposed scope of that policy is; and when he expects that policy to have been fully developed.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	10011
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>NHS England works in partnership with local commissioners and providers to ensure people with long-term conditions, such as hidradenitis suppurativa (HS), are supported to live healthily and independently and are empowered to take better control over the care they receive.</p><p> </p><p> </p><p> </p><p>The majority of patients with HS can be managed through routine access to primary and secondary care, including dermatology clinics, which is responsibility of the local National Health Service commissioners. Treatment and management of the condition involves antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe.</p><p> </p><p> </p><p> </p><p>For those patients with the more serious forms of HS, referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions, including HS, and has set out what providers must have in place in order to offer specialist dermatology care. This supports equity of access to a high quality service for patients wherever they live. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found by viewing the specialised dermatology service specification at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 10010 question first answered 16/09/2015 11:46:53 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

348398

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate his Department has made of the number of people with hidradenitis suppurativa in the UK; how much his Department has spent on research into hidradenitis suppurativa in the last four years; and what guidance his Department gives on support to be given through the NHS for people with hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	963
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom‘s leading charity for the condition. More information can be found at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx" target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p> </p><p><br> In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 962 964 965 question first answered 08/06/2015 10:54:00 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper